Table 1.
Baseline Sociodemographics and Respiratory Medication in All Patients Newly Diagnosed with COPD (N = 20,212), and Patients Categorized According to Whether They Had at Least One Severe Respiratory Event During Baseline (N = 955) or Not (N = 19,257)
| Overall | No Respiratory Eventa | 1+ Respiratory Event | |
|---|---|---|---|
| N = 20,212 | N = 19,257 | N = 955 | |
| n (%) | n (%) | n (%) | |
| Sex, n (%) | |||
| Female | 7859 (38.9) | 7563 (39.3) | 296 (31.0) |
| Male | 12,353 (61.1) | 11,694 (60.7) | 659 (69.0) |
| Age at index date, years | |||
| Mean (SD) | 55.0 (8.8) | 54.9 (8.8) | 58.0 (8.8) |
| Median (IQR) | 55 (48, 62) | 55 (48, 61) | 58 (51, 65) |
| Age at index date, years | |||
| 40–49 | 6145 (30.4) | 5961 (31.0) | 184 (19.3) |
| 50–59 | 7414 (36.7) | 7065 (36.7) | 349 (36.5) |
| 60–69 | 5329 (26.4) | 5019 (26.1) | 310 (32.5) |
| ≥ 70 | 1324 (6.6) | 1212 (6.3) | 112 (11.7) |
| Respiratory medication useb | |||
| None | 9511 (47.1) | 9152 (47.5) | 359 (37.6) |
| Reliever medication | |||
| None | 16,916 (83.7) | 16,183 (84.0) | 733 (76.8) |
| SABA | 3295 (16.3) | 3073 (16.0) | 222 (23.2) |
| SAMA | 2 (0.010) | 2 (0.01) | 0 (0.0) |
| Maintenance therapy | |||
| None | 17,626 (87.2) | 16,824 (87.4) | 802 (84.0) |
| ICS+LABA | 2103 (10.4) | 1983 (10.3) | 120 (12.6) |
| ICS monotherapy | 654 (3.2) | 626 (3.3) | 28 (2.9) |
| LAMA monotherapy | 147 (0.7) | 114 (0.6) | 33 (3.5) |
| LABA monotherapy | 82 (0.4) | 75 (0.4) | 7 (0.7) |
| ICS+LABA+LAMA | 69 (0.3) | 53 (0.3) | 16 (1.7) |
| LABA+LAMA | 19 (0.09) | 13 (0.07) | 6 (0.6) |
| ICS+LAMA | 6 (0.03) | 5 (0.03) | 1 (0.1) |
| Expectorant (R05 or R05F) | 9751 (48.2) | 9215 (47.9) | 536 (56.1) |
| Slow-release theophylline | 1077 (5.3) | 1002 (5.2) | 75 (7.9) |
| History of hospitalization | |||
| 1 | 2013 (10.0) | 1705 (8.9) | 308 (32.3) |
| ≥ 2 | 1781 (8.8) | 1274 (6.6) | 507 (53.1) |
| History of outpatient visits | |||
| 1 | 801 (4.0) | 767 (4.0) | 34 (3.6) |
| ≥ 2 | 18,999 (94.0) | 18,119 (94.1) | 880 (92.1) |
Notes: aRespiratory events during baseline included lower respiratory tract infection and acute respiratory failure; bDefined as at least one dispensation claim recorded in the 365 days prior to index date.
Abbreviations: COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids; IQR, interquartile range; LABA, long-acting β2-agonists; LAMA, long-acting muscarinic antagonists; SABA, short-acting β2-agonists; SAMA, short-acting muscarinic antagonists; SD, standard deviation.